MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
6.11
-0.05
-0.73%
Opening 11:16 12/04 EST
OPEN
6.20
PREV CLOSE
6.15
HIGH
6.35
LOW
6.05
VOLUME
839.06K
TURNOVER
0
52 WEEK HIGH
12.75
52 WEEK LOW
4.825
MARKET CAP
1.25B
P/E (TTM)
-4.8665
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BCRX last week (1127-1201)?
Weekly Report · 8h ago
Biocryst Pharmaceuticals Inc: Current report
Press release · 3d ago
BioCryst Pharmaceuticals Says It Will Receive A 20% Royalty On Annual Japanese Sales Below A Prespecified Threshold And An 80% Royalty On Annual Japanese Sales Above Prespecified Threshold
Benzinga · 4d ago
JPMorgan Recommends These 2 ‘Strong Buy’ Stocks With Over 60% Upside Potential
TipRanks · 4d ago
BioCryst announces approval of ORLADEYO (berotralstat) by Argentinean authorities
Healthcare biocryst announces approval of orladeyo (berotralstat) by argentinean authority. Bcrx +1.11% premarket to $5.45. Oral therapy is designed to prevent attacks of hereditary angioedema in adult and pediatric patients 12 years and older.
Seeking Alpha · 5d ago
Weekly Report: what happened at BCRX last week (1120-1124)?
Weekly Report · 11/27 09:03
JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower
Jp morgan bullish on six big biotechs, rates nine others neutral or lower. Insmed, denali, immunocore, crinetics, mirum and biocryst among those rated overweight. Investment bank was less keen on cervel therapeutics, alkermes and esperion.
Seeking Alpha · 11/25 21:32
NTNX, SFIX and GDGL are among after hour movers
Ntnx, sfix and gdgl are among after hour movers. Feam, ctkb, gtlb and mura are among the day's losers. 5e advanced materials and stitch fix were among the top gainers in the after hour market.
Seeking Alpha · 11/24 18:25
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers and commercializes oral, small-molecule medicines. The Company focuses on oral treatments for rare diseases, in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), BCX9930, BCX9250, PERAMIFLU (peramivir injection), galidesivir, and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. BCX9930 is an oral, potent, and selective small molecule inhibitor of Factor D. Galidesivir is a broad-spectrum antiviral that is active against viral families.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.